Physician profile
Ron Dunchok
NPI 1356331730
$2,958.24
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $701 · 2021: $720 · 2022: $703 · 2023: $42.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $505.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $436.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $262.59 | 2019-2022 | |
| Lilly USA, LLC | $199.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $186.80 | 2019-2022 | |
| Abbvie INC. | $150.47 | 2020-2021 | |
| Amarin Pharma, INC. | $136.97 | 2019-2022 | |
| Novo Nordisk INC | $104.87 | 2020-2022 | |
| Gilead Sciences, INC. | $101.11 | 2022 | |
| Amgen INC. | $99.87 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $97.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.60 | 2021-2022 | |
| Astellas Pharma US INC | $73.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.35 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.57 | 2019-2022 | |
| Sk Life Science, INC. | $43.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $42.37 | 2021 | |
| Philips North America LLC | $35.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $30.11 | 2021 | |
| Avanir Pharmaceuticals, INC. | $25.64 | 2022 | |
| Sumitomo Pharma America, INC. | $23.94 | 2023 | Gemtesa |
| Abbott Laboratories | $22.95 | 2020 | |
| Eisai INC. | $22.77 | 2020 | |
| Glaxosmithkline, LLC. | $21.25 | 2019 | |
| Biogen, INC. | $19.71 | 2021 | |
| Phadia US INC. | $19.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.12 | 2022 | |
| Dexcom, INC. | $18.08 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Dunchok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.